Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 1;18(11):1388-1390.
doi: 10.2215/CJN.0000000000000316. Epub 2023 Oct 3.

New Insights into the Effects of Etelcalcetide on Bone Health

Charles Ginsberg  1 , Joachim H Ix  1   2
Affiliations
Editorial

New Insights into the Effects of Etelcalcetide on Bone Health

Charles Ginsberg et al. Clin J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

J.H. Ix reports consultancy for Akebia, AstraZeneca, Bayer, Cincor, and Sanifit; research funding from Baxter International and Juvenile Diabetes Research Foundation; honoraria from Akebia, AstraZeneca, Bayer, Cincor, and Sanifit; advisory or leadership role for AlphaYoung; and other interests or relationships with Executive Board for Kidney Disease: Improving Global Outcomes (KDIGO). The remaining author has nothing to disclose.

Comment on

  • Changes in Bone Quality after Treatment with Etelcalcetide.
    Khairallah P, Cherasard J, Sung J, Agarwal S, Aponte MA, Bucovsky M, Fusaro M, Silberzweig J, Frumkin GN, El Hachem K, Schulman L, McMahon D, Allen MR, Metzger CE, Surowiec RK, Wallace J, Nickolas TL. Khairallah P, et al. Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1456-1465. doi: 10.2215/CJN.0000000000000254. Epub 2023 Aug 14. Clin J Am Soc Nephrol. 2023. PMID: 37574661 Free PMC article.

References

    1. Quarles LD Sherrard DJ Adler S, et al. . The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14(3):575–583. doi:10.1097/01.ASN.0000050224.03126.ad - DOI - PubMed
    1. Paik JM, Zhuo M, York C, Tsacogianis T, Kim SC, Desai RJ. Medication burden and prescribing patterns in patients on hemodialysis in the USA, 2013–2017. Am J Nephrol. 2021;52(12):919–928. doi:10.1159/000520028 - DOI - PMC - PubMed
    1. Khairallah P Cherasard J Sung J, et al. . Changes in bone quality after treatment with etelcalcetide. Clin J Am Soc Nephrol. 2023;18(11):1456–1465. doi:10.2215/CJN.0000000000000254 - DOI - PMC - PubMed
    1. Chertow GM Block GA Correa-Rotter R, et al. . The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–2494. doi:10.1056/NEJMoa1205624 - DOI - PubMed
    1. Block GA Martin KJ de Francisco ALM, et al. . Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–1525. doi:10.1056/NEJMoa031633 - DOI - PubMed